Premium
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study
Author(s) -
Kirschbaum Mark H.,
Frankel Paul,
Synold Timothy W.,
Zain Jasmine,
Claxton David,
Tuscano Joseph,
Newman Edward M.,
Gandara David R.,
Lara Primo N.
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14333
Subject(s) - aflibercept , medicine , cancer , myelodysplastic syndromes , vascular endothelial growth factor , oncology , vegf receptors , chemotherapy , bone marrow , bevacizumab
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom